methyl 2-chloro-6-(4-methylpiperazin-1-yl)isonicotinate, 1g

BenzaMide, N-[4-[(4-ethyl-1-piperazinyl)Methyl]-3-(trifluoroMethyl)phenyl]-4-Methyl-3-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]aMino]-, 98%, 50mg

5-Bromo-o-anisaldehyde>98.0%(GC)25g

2-Amino-3-(4-iodophenyl)propanoic acid, 95.0%, 250mg

Sodium 4-(2-(2-(2-chloro-3-(2-(3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-2-yl)vinyl)cyclohex-2-en-1-ylidene)ethylidene)-3,3-dimethylindolin-1-yl)butane-1-sulfonate, 98%, 1g

4,6-Dichloro-5-pyrimidinecarboxaldehyde, 97.0%, 25g

Urea, N-(6,8-difluoro-2-methyl-4-quinolinyl)-N'-[4-(dimethylamino)phenyl]-, 98%, 250mg

Recipiente de cristalización ROTILABO® con pico, 500 ml, 115 mm, 10 Unidad(es)

1-(2,4-Diethoxyphenyl)ethanone, 97.0%, 250mg

1-(4-Aminophenyl)-3-morpholino-5,6-dihydropyridin-2(1H)-one, 95.0%, 10g

2,2-Dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azanonadecan-19-yl 4-methylbenzenesulfonate, 98%, 1g

Methyl 4-bromo-5-cyanothiophene-2-carboxylate, 95+%, 250mg

(3-Chlorothiophen-2-yl)methanamine, 97%, 100mg